Is ATRS a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

3,784 people get ATRS articles and Market Currents by email alert.

Get email alerts on ATRS »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Antares: Reiteration Of My Buy Recommendation
Smith On Stocks • Thu, May 16 • 19 Comments
Contraceptive Ring: Another Under-The-Radar Catalyst For Antares
Ali Yasar • Wed, May 15 • 15 Comments
Antares: Challenger Emerging Against 400-Year Old Condom
Ali Yasar • Thu, May 2 • 30 Comments
Seizing The Blockbuster Opportunity Buried In Conservative Modeling At Antares Pharma
Ali Yasar • Thu, Apr 25 • 52 Comments
A Deep Dive Into Antares Pharma's Buyout Thesis
Ali Yasar • Tue, Mar 26 • 28 Comments
Antares: A Compelling Long-Term Investment
Alexander Maxwell • Thu, Mar 21 • 17 Comments
Savvy Investors Discover Antares' Growing Revenue Stream
James Stocklasar Thomas Jr. • Thu, Jan 17 • 15 Comments
Antares Rallies Quickly And Confidently On Newest Developments
Brian L. Wilson • Fri, Jan 11 • 10 Comments
Why Is Antares Rising So Quickly?
James Stocklasar Thomas Jr. • Wed, Jan 9 • 34 Comments
Why Growth Stock Antares Is Moving Higher
James Stocklasar Thomas Jr. • Mon, Jan 7 • 29 Comments
Unlocking Antares' Vision For Arthritis Patients
Shadow Play • Fri, Dec 7, 2012 • 31 Comments
Why Antares Pharma Will Be A Powerhouse In The Future
Shadow Play • Wed, Nov 14, 2012 • 27 Comments
Dilution Is The Solution To Pollution
Eric Wick • Tue, Oct 9, 2012 • 22 Comments
Led By Vibex MTX, Antares' Pipeline Is Bursting With New Products
Smith On Stocks • Mon, Sep 10, 2012 • 20 Comments
Thursday's Biotech Opportunity: Antares Pharma
James Stocklasar Thomas Jr. • Thu, Aug 23, 2012 • 20 Comments
Antares Pharma Getting Ready To Break Out Again
Tactical Investor • Thu, Aug 16, 2012 • 38 Comments
Antares Pharma Explained: Why It's The Best Small Cap Long Term Investment In The Market
Scott Matusow • Mon, Aug 13, 2012 • 41 Comments
Why Getting Under The Skin May Enhance Antares' Near-Term Revenue Stream
James Stocklasar Thomas Jr. • Tue, Jul 10, 2012 • 30 Comments
3 Internal Signs Of Antares On The Move
James Stocklasar Thomas Jr. • Mon, Jul 9, 2012 • 26 Comments
10 Verifiable Reasons Why Antares Is An Excellent Investment
James Stocklasar Thomas Jr. • Thu, Jul 5, 2012 • 44 Comments

To learn more about Seeking Alpha Pro, click here.

Wednesday's Biotech Catalyst Trade Watch List
Scott Matusow • Wed, Jun 12 • 10 Comments
4 Top Small Cap Biotech Acquisition Targets
Scott Matusow • Fri, May 31 • 12 Comments
Long-Term Biotech: 3 Names To Discover Now
Putnam Kling • Tue, May 21 • 4 Comments
SmithOnStocks Opines On Stocks: May 19th Edition
Smith On Stocks • Sun, May 19 • 12 Comments
Thursday's BioPharma Trade Movers
Scott Matusow • Thu, Apr 18 • 29 Comments
Reviving The Blockbuster Potential Of LibiGel For BioSante And Antares Pharma
Ali Yasar • Mon, Apr 8 • 18 Comments
Bio Run-Ups: What To Expect In The Next Few Months
Alexander Maxwell • Fri, Mar 22 • 33 Comments
Obagi Medical Products Acquired Wednesday, These Biotechs May Be Next
Scott Matusow • Thu, Mar 21 • 46 Comments
3 Undiscovered Biotech Companies For The Healthcare Investor
William Sterling • Mon, Mar 11 • 31 Comments
Following Crashing Biotechs - 5 Bargains To Consider
Craig Keolanui • Tue, Feb 26 • 5 Comments
Recognizing Leadership In Biotech: A Critical Facet Of The Diligence Process
Nouvelle Asset Management • Thu, Feb 21 • 9 Comments
Upcoming NDA, Potential Partner Add Further Investment Value For Pozen
Scott Matusow • Wed, Feb 13 • 13 Comments
Cramer's Lightning Round - Cisco Should Be Fine (1/16/13)
SA Editor Miriam Metzinger • Thu, Jan 17 • 9 Comments
Legendary Investor Icahn Still Slugging Away With Enzon Pharma
Scott Matusow • Tue, Jan 8 • 18 Comments
Strong Small Cap Biopharma Catalyst Trades And Investments For Consideration
Scott Matusow • Tue, Dec 18, 2012 • 29 Comments
Why Cash Overrules The Momentary Market Bounce
James Stocklasar Thomas Jr. • Tue, Nov 27, 2012 • 14 Comments
Why I'm 'In Cash' For Biotechs In A Bearish Market
James Stocklasar Thomas Jr. • Wed, Nov 21, 2012 • 37 Comments
3 Small Cap Bio-Pharmas Offering Good Upside Potential
Scott Matusow • Tue, Nov 20, 2012 • 33 Comments
$33,000 Portfolio: Mostly Cash Ahead Of Elections And Snow-Hurricanes
Joe Springer • Tue, Oct 30, 2012 • 23 Comments
Interview: Delcath's CEO Provides Details About The Resubmission Of The FDA's New Drug Application For CHEMOSAT
Ben Yoffe • Wed, Oct 3, 2012 • 7 Comments

Antares Pharma's CEO Presents at 38th Annual Deutsche Bank Health Care Conference (Transcript)
Thu, May 30
Antares Pharma Management Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 8 • 1 Comment
Antares Pharma Management Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Mar 13 • 1 Comment

Subcutaneous, Self-Administered Methotrexate for Rheumatoid Arthritis Demonstrated Significantly Greater Bioavailability over Current Standard of Care

Business Wire (Thu, 7:00AM)
Antares Pharma to Present at the Jefferies 2013 Global Healthcare Conference

Business Wire (May 29, 2013)
Antares Pharma to Present at the Deutsche Bank Securities, Inc. 38th Annual Health Care Conference

Business Wire (May 24, 2013)
Antares Pharma Welcomes Marvin Samson to Board of Directors

Business Wire (May 23, 2013)
Antares Pharma to Present at the Bank of America Merrill Lynch 2013 Healthcare Conference

Business Wire (May 9, 2013)
Antares Pharma Reports First Quarter 2013 Operating and Financial Results

Business Wire (May 8, 2013)
Antares Pharma to Host First Quarter 2013 Operating and Financial Results Conference Call

Business Wire (May 1, 2013)
Antares Pharma Announces the Issuance of a New Patent on VIBEX™ Device Platform

Business Wire (Apr 16, 2013)
Antares Pharma Announces Notice of Allowance for New Patent on VIBEX™ QuickShot Device

Business Wire (Apr 5, 2013)
Antares Pharma Announces First Shipment of Commercial VIBEX™ Auto-Injector Devices to Teva

Business Wire (Apr 3, 2013)
Antares Pharma Reports Fourth Quarter and Full Year 2012 Operating and Financial Results

Business Wire (Mar 13, 2013)
Antares Pharma to Host Fourth Quarter 2012 Call

Business Wire (Mar 6, 2013)
Antares Pharma Announces FDA Acceptance of New Drug Application for OTREXUP™

Business Wire (Feb 27, 2013)
Antares Pharma to Present at the Cowen and Company 33rd Annual Healthcare Conference

Business Wire (Feb 26, 2013)
Antares Pharma to Participate in the 2013 RBC Capital Markets’ Healthcare Conference

Business Wire (Feb 20, 2013)
Lightning Round: Total SA, Cisco & More

at CNBC.com (Jan 16, 2013)
Antares Pharma Announces Submission of New Drug Application for OTREXUP™

Business Wire (Dec 17, 2012)
Antares Pharma to Present at the Oppenheimer 23rd Annual Healthcare Conference

Business Wire (Dec 5, 2012)
Lightning Round: Apple, Linn Energy and More

at CNBC.com (Dec 3, 2012)
Antares Pharma Announces Positive Results from Final MTX Medi-Jet™ Clinical Study

Business Wire (Nov 13, 2012)

ATRS vs. ETF Alternatives

Company Description

Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies, and topical gel-based medicines worldwide. The companys products include Tjet/Zomajet, the needle-free auto... More

Sector: Healthcare

Industry: Drug Delivery & Accessories

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 8, 7:10 AM Antares Pharmaceuticals (ATRS): Q1 EPS of -$0.03 in-line. Revenue of $4.53M misses by $0.59M. (PR) 2 Comments [Earnings, Breaking News, Healthcare]
Friday, April 5, 8:01 AM Antares Pharma (ATRS) gets a Notice of Allowance from the U.S. Patent Trade Office regarding the company's patent application for the VIBEX QuickShot. ATRS said Thursday that the first shipment of the auto-injector devices will be on their way to Teva (TEVA) by the end of Q1. Shares +2% premarket. 1 Comment [Healthcare, On the Move]
Wednesday, April 3, 12:37 PM Antares Pharma (ATRS +0.3%) says the first shipment of commercial-ready VIBEX auto-injector devices will be shipped to TEVA at the end of Q1. Anatares will receive a negotiated purchase price for each device sold, as well as a royalty on sales. 1 Comment [Healthcare, Global & FX]
Wednesday, March 13, 7:02 AM Antares Pharma (ATRS): Q4 EPS of -$0.04 misses by $0.01. Revenue of $5.5M beats by $0.14M. (PR) 6 Comments [Earnings, Breaking News, Healthcare]
Wednesday, March 13, 12:05 AM Notable earnings before Wednesday’s open: AH, AMRC, ATRS, EXPR, KRO, PERI, SNSS, TA Comment! [Earnings]
Tuesday, March 12, 5:30 PM Notable earnings before Wednesday’s open: AH, AMRC, ATRS, EXPR, KRO, PERI, SNSS, TA Comment! [Earnings]
Tuesday, November 13, 2012, 8:44 AM Antares Pharma's (ATRS) MTX Medi-Jet injection device performed well in treating rheumatoid arthritis sufferers with Methotrexate compared with the oral version of the medicine. The MTX Medi-Jet enables patients with difficulty using their hands to inject the treatment into themselves, thereby avoiding the need for weekly injections by a professional. (PR) 1 Comment [Healthcare]
Wednesday, November 7, 2012, 7:56 AM Altiris (ATRS): Q3 EPS of -$0.03 misses by $0.01. Revenue of $5.7M (+45% Y/Y) in-line. Shares -4.2% premarket. (PR) Comment! [Earnings, Healthcare, On the Move]
Wednesday, October 3, 2012, 12:45 PM Midday top 10 gainers: SRPT +162%. BIOL +38%. VRNG +25%. OCN +16%. KFS +16%. ASPS +14%. SNFCA +12%. TRU +10%. HOV +10%. ICAD +10%.
Top 10 Losers: GST -21%. LEAP -16%. XRTX -15%. THTI -13%. PBM -12%. SSY -10%. HOLL -10%. KRA -10%. ATRS -9%. KIOR -9%. 2 Comments [On the Move]
Wednesday, October 3, 2012, 9:41 AM Antares Pharma (ATRS) slumps 7.4% to $4.07 after pricing an offering of 12.5M shares at $4 each, resulting in net proceeds of $47M. The underwriters have a 30-day option to buy up to 1.875M extra shares. (PR) 1 Comment [Healthcare, On the Move]
Wednesday, October 3, 2012, 9:10 AM Premarket gainers: SRPT +107%. BIOL +14%. GENE +13%. ROYL +9%.
Losers: XRTX -9%. ATRS -7%. RIGL -6%. Comment! [On the Move]
Tuesday, September 25, 2012, 11:46 AM Antares Pharma (ATRS +11%) jumps after reporting positive results from its Actual Human Use study, to assess the effectiveness of self-administered Vibex Methotrexate for adult patients with rheumatoid arthritis. The company said that the results show that self-administration of the drug is safe and well tolerated. All 101 patients were able to self-administer the medication successfully following standardized training and review of written instructions. 4 Comments [Healthcare, On the Move]
Tuesday, September 25, 2012, 9:10 AM Premarket gainers: GENE +14%. DARA +13%. PPHM +8%. ATRS +8%. PURE +6%. UDRL +6%. ROSG +6%.
Losers: GEVO -16%. TSLA -8%. KEG -8%. Comment! [On the Move]
Friday, August 10, 2012, 1:36 PM Shares of Antares Pharma (ATRS -9.1%) continue their slide today after its second-quarter loss widened and results missed analyst estimates on Wednesday. Net profit was hit by bottom line pressure from higher investment expenses related to the development of its Vibex MTX auto injector for the treatment of rheumatoid arthritis, along with an increase in support personnel. 9 Comments [Healthcare, On the Move]
Friday, August 10, 2012, 9:10 AM Premarket gainers: FIO +23%. JNS +18%. XIN +14%. BYI +7%. RIMM +6%.
Losers: UBNT -39%. RNDY -22%. SPRD -13%. PIP -11%. ATRS -6%. CPST -6%. DK -5%. Comment! [On the Move]
Wednesday, August 8, 2012, 9:10 AM Premarket gainers: WFR +31%. DF +28%. RAX +14%. LAMR +13%. CBB +12%. SODA +8%. CLWR +7%. KTOS +7%. ESRX +6%. HPQ +6%.
Losers: EZCH -21%. GIVN -16%. PCLN -15%. ATRS -9%. ASTM -9%. WCRX -8%. RL -7%. EXAS -5%. RENN -5%. Comment! [On the Move]

ElysianFieldsofJamaicaPlain
$ATRS up 5.26% in early trading. Big pop
Jun 5, 9:17 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

CrAzY-MiKe
$ATRS
Jun 2, 7:15 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
My new article out at http://seekingalpha.com/a/vczn New Vid at http://bit.ly/19jbbZn $ATRS $BDSI
May 28, 10:14 AM
Reply (1)

• !Report Abuse
View all 1 replies
EnderisLegend: still holding $BDSI?
May 31, 1:03 PM
• !Report Abuse
Add a reply...

140 characters

bull_market_somewhere
been in $ATRS since 2010 (when it was $AIS), looking for a big move or a buyout eventually.
May 3, 10:52 AM
Reply (3)

• !Report Abuse
View all 3 replies
bull_market_somewhere: this year has been a nailbiter, very range bound.
May 3, 2:56 PM
• !Report Abuse
gbstern13: Don't get impatient. You've likely doubled since 2010, some possible catalysts in next year, little short term risk. Stay the course.
May 6, 1:28 PM
• !Report Abuse
Add a reply...

140 characters

Big Dummy
$ATRS a heck of a coaster ride. This stock is surely sound, because they are not a one hit wonder. ONE MUST wonder how low she will go.
Feb 23, 7:54 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

djbigley
$ATRS What's with the sell-off ????
Feb 20, 9:58 AM
Reply (2)

• !Report Abuse
View all 2 replies
Closet Iguana: Profit taking from yesterday
Feb 20, 10:16 AM
• !Report Abuse
Ocean Man: Stocklaser stopped pumping it around $4.30.
Feb 20, 3:57 PM
• !Report Abuse
Add a reply...

140 characters

JoeChang23
Cramer & AF are rite... $ATRS is a lousy company
Feb 15, 4:34 AM
Reply (6)

• !Report Abuse
View all 6 replies
JoeChang23: Don't underestimate AF, he was rite many times & saved many retail investors from catastrophic stocks such as CLSN, CPRX, AMRN, PPHM.
Feb 27, 10:46 AM
• !Report Abuse
jsiebel720: ATRS is not a risky cancer or drug biotech company; Its profile is different; maybe you can give AF some credibility, but Cramer has none.
Feb 27, 12:35 PM
• !Report Abuse
Add a reply...

140 characters

Shadow Play
$ATRS started as a buy by Jefferies
12/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Shadow Play
I see $ATRS meditating from the 3.60's-4.10's until late January. Once the Vibex MTX filing comes to light with FDA, then it pushes to $5.
12/11/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
$ATRS short term call PT -- $4 range complete @ http://seekingalpha.com/a/lurn
11/26/12
Reply (4)

• !Report Abuse
View all 4 replies
TDPeterson123: Thanks, Scott. The Teva investor conference on 12/11 could also be a catalyst event to ATRS (some speculate significantly so).
11/28/12
• !Report Abuse
TDPeterson123: Until the "Fiscal Cliff" ordeal reaches some sort of resolution we'll see a volatile market. 11th hour if it gets resolved this year.
11/28/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Scott Matusow
My new article out at http://seekingalpha.com/a/vczn New Vid at http://bit.ly/19jbbZn $ATRS $BDSI
May 28, 10:14 AM
Reply (1)

• !Report Abuse
View all 1 replies
EnderisLegend: still holding $BDSI?
May 31, 1:03 PM
• !Report Abuse
Add a reply...

140 characters

bull_market_somewhere
been in $ATRS since 2010 (when it was $AIS), looking for a big move or a buyout eventually.
May 3, 10:52 AM
Reply (3)

• !Report Abuse
View all 3 replies
bull_market_somewhere: this year has been a nailbiter, very range bound.
May 3, 2:56 PM
• !Report Abuse
gbstern13: Don't get impatient. You've likely doubled since 2010, some possible catalysts in next year, little short term risk. Stay the course.
May 6, 1:28 PM
• !Report Abuse
Add a reply...

140 characters

JoeChang23
Cramer & AF are rite... $ATRS is a lousy company
Feb 15, 4:34 AM
Reply (6)

• !Report Abuse
View all 6 replies
JoeChang23: Don't underestimate AF, he was rite many times & saved many retail investors from catastrophic stocks such as CLSN, CPRX, AMRN, PPHM.
Feb 27, 10:46 AM
• !Report Abuse
jsiebel720: ATRS is not a risky cancer or drug biotech company; Its profile is different; maybe you can give AF some credibility, but Cramer has none.
Feb 27, 12:35 PM
• !Report Abuse
Add a reply...

140 characters

djbigley
$ATRS What's with the sell-off ????
Feb 20, 9:58 AM
Reply (2)

• !Report Abuse
View all 2 replies
Closet Iguana: Profit taking from yesterday
Feb 20, 10:16 AM
• !Report Abuse
Ocean Man: Stocklaser stopped pumping it around $4.30.
Feb 20, 3:57 PM
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$ATRS short term call PT -- $4 range complete @ http://seekingalpha.com/a/lurn
11/26/12
Reply (4)

• !Report Abuse
View all 4 replies
TDPeterson123: Thanks, Scott. The Teva investor conference on 12/11 could also be a catalyst event to ATRS (some speculate significantly so).
11/28/12
• !Report Abuse
TDPeterson123: Until the "Fiscal Cliff" ordeal reaches some sort of resolution we'll see a volatile market. 11th hour if it gets resolved this year.
11/28/12
• !Report Abuse
Add a reply...

140 characters

Cabeza Howe
$ATRS: $3.60 (-7.1%) in a day. But one year from now you will be happy you bought in today.
11/15/12
Reply (6)

• !Report Abuse
View all 6 replies
Cabeza Howe: After counting cash take-in from options/warrants exercises, annual cash burn rate is only $1.5M. Also biotechs not sensitive to economy.
11/16/12
• !Report Abuse
Cabeza Howe: It's the fears that's driving all small biopharmas lower regardless of quality. Whoever buys quality will be rewarded over time.
11/16/12
• !Report Abuse
Add a reply...

140 characters

jen2xtreme
Looking for a re-entry for $ATRS, how low will it go...
10/18/12
Reply (3)

• !Report Abuse
View all 3 replies
jsiebel720: NOT!!!!
11/10/12
• !Report Abuse
jen2xtreme: He was close, it got down to 3.51 on Nov 7th.
11/11/12
• !Report Abuse
Add a reply...

140 characters

Joe Springer
Here's the latest $33,000 article, we stand at $35,814.50 http://seekingalpha.com/a/kltb $PSTI $SPPI $ARNA $ACI $MNKD $IBIO $ATRS #Sandy
10/30/12
Reply (3)

• !Report Abuse
View all 3 replies
Joe Springer: Hi IV, May 25 was start, I try to limit the trades so that it is replicable, 2 month average per trade about: http://seekingalpha.com/p/e7pf
10/30/12
• !Report Abuse
sundate36: Is anyone buying ARNA at 8.00 today?
10/31/12
• !Report Abuse
Add a reply...

140 characters

Joe Springer
$33,000 Portfolio -- Selling biotech to put proceeds in $MNKD, love the price and they are funded now, more to come $PSTI $IBIO $ATRS $ACI
10/18/12
Reply (5)

• !Report Abuse
View all 5 replies
joe kelly: As a percentage of portfolio, how large is the MNKD investment Joe?
10/19/12
• !Report Abuse
Joe Springer: That would put it in the 20% range roughly, I have to do the math Joe
10/19/12
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
My Long Watch List For Swing Trading http://bit.ly/QW9b0H FDX GXP MCP WLT PNR ATRS AAPL GWW EDU SHLD NLSN WYNN ALXN BEAV VZ WTSL
10/12/12
Reply (1)

• !Report Abuse
View all 1 replies
Hillbilly Stock Star: WYNN, AAPL, OKE,.........my top three longs.
10/12/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
My explanation why I sold Antares (ATRS) + some charting analysis and commentary...: http://bit.ly/QIwlHV
10/3/12
Reply (12)

• !Report Abuse
View all 12 replies
Noreika: Man, I wish I took profits on my VRNG position today. Walstreet shenanagins.
10/5/12
• !Report Abuse
sheldond: I did and VRNG has at least two more trades in it for me if they do make an offering. Out at 5.25 and feeling good.
10/6/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$FOLD Chart and opinion, Further $ATRS commentary. To start, I remark I am still bullish on Antares @ http://bit.ly/Q0yD3t
10/5/12
Reply (3)

• !Report Abuse
View all 3 replies
StockMatusow: yes
10/5/12
• !Report Abuse
sheldond: Love it Scott, Great ideas here about Fold. I hold the Fold and so should you.
10/6/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$ATRS is my best long term investment pick concerning small caps. $23 - $25 a share price target in 2015
10/2/12
Reply (27)

• !Report Abuse
View all 27 replies
StockMatusow: ill look at NKTR. I'm liking FOLD now. on ATRS, I have to see how the next few months go, but I would say 15 to 20 now
10/5/12
• !Report Abuse
phemale60: Scott, any opinion on ACHN? Seems to be on a tear lately - gone up so much hate to jump on, yet keeps moving up. Thanks.
10/5/12
• !Report Abuse
Add a reply...

140 characters

phemale60
ATRS - What the heck!? same time Pfizer gives them $750,000 they dilute shares? tanking aft. hrs - hate to sell but why take loss
10/2/12
Reply (17)

• !Report Abuse
View all 17 replies
DAG1996: CLSN is my favorite but it already tripled since i bought so not sure if it has more room to run. VICL might. all 3 have upcoming catalysts.
10/4/12
• !Report Abuse
DAG1996: if i were able to buy more now, i would consider ASTX, BLRX & CLDX. because I can't buy more now, i haven't done thorough dd on them tho.
10/4/12
• !Report Abuse
Add a reply...

140 characters

z28gator
ATRS on it's way back! Scott Matusow called it a few days ago--$5 before October.
9/18/12
Reply (7)

• !Report Abuse
View all 7 replies
spybreaker: yeah, must be one of those "feel good" effects. It's going nuts now - up 2.38% premarket.
9/19/12
• !Report Abuse
phemale60: presently up .15 -- moving up nice again!
9/19/12
• !Report Abuse
Add a reply...

140 characters

ATRS Antares Pharma Inc

ATRS

Antares Pharma Inc